33
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies.

      Journal of Antimicrobial Chemotherapy
      Acinetobacter Infections, drug therapy, epidemiology, microbiology, Acinetobacter baumannii, drug effects, Anti-Bacterial Agents, pharmacology, therapeutic use, Asia, Colistin, Drug Resistance, Multiple, Bacterial, Drug Therapy, Combination, methods, Europe, Humans, Prevalence

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Colistin is the last resort for treatment of multidrug-resistant Acinetobacter baumannii. Unfortunately, resistance to colistin has been reported all over the world. The highest resistance rate was reported in Asia, followed by Europe. The heteroresistance rate of A. baumannii to colistin is generally higher than the resistance rate. The mechanism of resistance might be loss of lipopolysaccharide or/and the PmrAB two-component system. Pharmacokinetic/pharmacodynamic studies revealed that colistin monotherapy is unable to prevent resistance, and combination therapy might be the best antimicrobial strategy against colistin-resistant A. baumannii. Colistin/rifampicin and colistin/carbapenem are the most studied combinations that showed promising results in vitro, in vivo and in the clinic. New peptides showing good activity against colistin-resistant A. baumannii are also being investigated.

          Related collections

          Author and article information

          Comments

          Comment on this article